@article{caa973cf5a454683b55af5bd35629048,
title = "Targeting extranuclear histones to alleviate acute and chronic inflammation",
abstract = "Extracellular histones instigate an inflammatory triad – centered on cytotoxicity, immune cell stimulation, and coagulation – ultimately shaping the dynamics and outcome of various inflammatory pathologies. Given the virtual absence of beneficial functions of histones in the extracellular space, in recent years a number of interference strategies have emerged. In this review we summarize pathogenic functions of extracellular histones and highlight current developments of therapeutic interference. Finally, we elaborate on the current status of preclinical attempts to interfere with extracellular histones in the context of a focus on sepsis and cardiovascular diseases, both of which are leading causes of mortality worldwide.",
keywords = "histone, inflammation, neutrophil",
author = "Nicolaes, {Gerry A.F.} and Oliver Soehnlein",
note = "Funding Information: O.S. receives funding from the Deutsche Forschungsgemeinschaft (TRR332 projects A2 & Z1, CRC1009 project A13, CRC1123 project A6, CRU342 project A1), the Interdisziplin\u00E4res Zentrum f\u00FCr Klinische Forschung (IZKF) and the IMF Program of the Medical Faculty M\u00FCnster. O.S. and G.A.F.N. receive funding from the EU (PRAETORIAN Doctoral Network) and Novo Nordisk. O.S. and G.A.F.N. receive support from Novo Nordisk to study means to interfere with histone cytotoxicity. O.S. and G.A.F.N. hold a patent on histone neutralization (WO2019122127A1). G.A.F.N. is advisor and shareholder of Matisse Pharmaceuticals B.V. a company that holds a license to a patent of the Maastricht University on the use of non-anticoagulant heparin the treatment of inflammatory diseases and sepsis (US9155756B2). Funding Information: O.S. receives funding from the Deutsche Forschungsgemeinschaft ( TRR332 projects A2 & Z1, CRC1009 project A13, CRC1123 project A6, CRU342 project A1), the Interdisziplin\u00E4res Zentrum f\u00FCr Klinische Forschung (IZKF) and the IMF Program of the Medical Faculty M\u00FCnster. O.S. and G.A.F.N. receive funding from the EU (PRAETORIAN Doctoral Network) and Novo Nordisk. Publisher Copyright: {\textcopyright} 2024 The Author(s)",
year = "2024",
month = jul,
doi = "10.1016/j.tips.2024.05.008",
language = "English",
volume = "45",
pages = "651--662",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Ltd",
number = "7",
}